| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A486 | Medimmune patent anti-Siglec-15 Featured |
|
|
| A487 | Epratuzumab Featured | Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases. |
|
| A488 | Pinatuzumab Featured | Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL). |
|
| A489 | Inotuzumab-CLM Featured |
|
|
| A490 | Anti-Siglec-2/CD22 Antibody (NCI m971) Featured |
|
|
| A491 | Anti-Siglec-2/CD22 Antibody (NCI m972) Featured |
|
|
| A492 | IMGN779 Featured |
|
|
| A493 | Vadastuximab Featured | Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. |
|
| DC67102 | D-Glucose-¹³C6 Featured | D-Glucose-13C6 is a stable isotope-labeled counterpart of D-glucose (HY-B0389). D-Glucose-13C6 can be used as a metabolic tracer to trace glucose-related synthetic catabolism or as synthesis ingredient, minimal media reagent, and internal standard. |
|
| A494 | Gemtuzumab Featured | Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. |
|
| A495 | Refanezumab Featured | Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke. |
|
| A496 | Lirentelimab Featured | Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis. |
|
| A497 | BI 765063 Featured |
|
|
| A498 | Hospital for Sick Children patent anti-SIRPA Featured |
|
|
| A499 | KWAR 23 Featured | KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research. |
|
| A500 | SGN-CD352A Featured |
|
|
| A501 | Azintuxizumab Featured | Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin. |
|
| A502 | PDL241 Featured |
|
|
| A503 | Elotuzumab Featured | Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents. |
|
| A504 | Idactamab Featured | Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5). |
|
| A505 | VB1-050 Featured |
|
|
| A506 | LY2928057 Featured |
|
|
| A507 | Amgen patent anti-Ferroportin Featured |
|
|
| A508 | ASG-5ME Featured |
|
|
| A509 | Agilvax Patent Anti-Slc7A11 Featured |
|
|
| A510 | Sirtratumab Featured | Sirtratumab is a human Igγ2 monoclonal antibody against SLIT and NTRK-like family 6 (Slitrk6). Sirtratumab can be used in research of cancer. |
|
| A511 | Latozinemab Featured | Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research. |
|
| A512 | Blosozumab Featured | Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis. |
|
| A513 | Setrusumab Featured | Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer. |
|
| A514 | Romosozumab Featured | Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis. |
|
